Allianz Asset Management GmbH Purchases Shares of 48,335 Global Blood Therapeutics Inc (GBT)

Allianz Asset Management GmbH purchased a new position in shares of Global Blood Therapeutics Inc (NASDAQ:GBT) during the 4th quarter, Holdings Channel reports. The institutional investor purchased 48,335 shares of the company’s stock, valued at approximately $1,902,000.

Several other large investors have also recently made changes to their positions in GBT. Point72 Asset Management L.P. boosted its stake in shares of Global Blood Therapeutics by 189.5% during the 3rd quarter. Point72 Asset Management L.P. now owns 2,022,700 shares of the company’s stock worth $62,805,000 after acquiring an additional 1,323,934 shares in the last quarter. Citadel Advisors LLC boosted its stake in shares of Global Blood Therapeutics by 161.7% during the 4th quarter. Citadel Advisors LLC now owns 716,611 shares of the company’s stock worth $28,199,000 after acquiring an additional 442,828 shares in the last quarter. Janus Henderson Group PLC boosted its stake in shares of Global Blood Therapeutics by 43.8% during the 3rd quarter. Janus Henderson Group PLC now owns 1,415,558 shares of the company’s stock worth $43,953,000 after acquiring an additional 431,325 shares in the last quarter. Perceptive Advisors LLC boosted its stake in shares of Global Blood Therapeutics by 8.4% during the 3rd quarter. Perceptive Advisors LLC now owns 4,264,066 shares of the company’s stock worth $132,399,000 after acquiring an additional 330,139 shares in the last quarter. Finally, Orbimed Advisors LLC boosted its stake in shares of Global Blood Therapeutics by 10.2% during the 3rd quarter. Orbimed Advisors LLC now owns 2,393,635 shares of the company’s stock worth $74,322,000 after acquiring an additional 221,700 shares in the last quarter. 85.40% of the stock is currently owned by institutional investors and hedge funds.

How to Become a New Pot Stock Millionaire

Shares of GBT stock opened at $48.15 on Friday. Global Blood Therapeutics Inc has a 52 week low of $24.02 and a 52 week high of $68.05. The stock has a market capitalization of $2,554.34, a P/E ratio of -17.51 and a beta of 4.31.

Global Blood Therapeutics (NASDAQ:GBT) last posted its earnings results on Tuesday, February 27th. The company reported ($0.94) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.72) by ($0.22). analysts predict that Global Blood Therapeutics Inc will post -3.72 earnings per share for the current year.

GBT has been the topic of several research analyst reports. Zacks Investment Research raised Global Blood Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, December 6th. Wedbush reissued an “outperform” rating and set a $73.00 price target on shares of Global Blood Therapeutics in a research note on Friday, December 15th. Nomura boosted their price target on Global Blood Therapeutics to $91.00 and gave the stock a “buy” rating in a research note on Monday, December 11th. Oppenheimer set a $79.00 price target on Global Blood Therapeutics and gave the stock a “buy” rating in a research note on Tuesday, December 12th. Finally, Cantor Fitzgerald set a $61.00 price target on Global Blood Therapeutics and gave the stock a “buy” rating in a research note on Monday, December 11th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and eleven have given a buy rating to the company’s stock. Global Blood Therapeutics presently has a consensus rating of “Buy” and an average target price of $70.69.

In other Global Blood Therapeutics news, insider Peter Radovich sold 812 shares of the business’s stock in a transaction on Thursday, February 1st. The stock was sold at an average price of $57.30, for a total value of $46,527.60. Following the completion of the transaction, the insider now directly owns 6,221 shares in the company, valued at approximately $356,463.30. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Jung Choi sold 3,000 shares of the business’s stock in a transaction on Friday, March 16th. The shares were sold at an average price of $54.15, for a total value of $162,450.00. Following the completion of the transaction, the insider now owns 139,277 shares of the company’s stock, valued at $7,541,849.55. The disclosure for this sale can be found here. In the last ninety days, insiders sold 54,911 shares of company stock worth $3,112,352. 5.30% of the stock is owned by corporate insiders.

ILLEGAL ACTIVITY NOTICE: “Allianz Asset Management GmbH Purchases Shares of 48,335 Global Blood Therapeutics Inc (GBT)” was reported by Ticker Report and is the sole property of of Ticker Report. If you are accessing this story on another website, it was stolen and reposted in violation of U.S. & international copyright legislation. The legal version of this story can be viewed at https://www.tickerreport.com/banking-finance/3294909/allianz-asset-management-gmbh-purchases-shares-of-48335-global-blood-therapeutics-inc-gbt.html.

About Global Blood Therapeutics

Global Blood Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel therapeutics to treat grievous blood-based disorders. Its lead product candidate is voxelotor, an oral once-daily therapy that modulates hemoglobin's affinity for oxygen, which is in Phase 3 clinical trials in adult and adolescent patients with sickle cell disease (SCD), as well as in evaluating the safety and pharmacokinetics of single and multiple doses of voxelotor in a Phase 2a clinical trial of adolescent and pediatric patients with SCD.

Want to see what other hedge funds are holding GBT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Global Blood Therapeutics Inc (NASDAQ:GBT).

Institutional Ownership by Quarter for Global Blood Therapeutics (NASDAQ:GBT)

Receive News & Ratings for Global Blood Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Global Blood Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Sanchez Energy  Expected to Announce Earnings of $0.20 Per Share
Sanchez Energy Expected to Announce Earnings of $0.20 Per Share
Analyzing DistributionNOW  and Its Rivals
Analyzing DistributionNOW and Its Rivals
Old Second Bancorp, Inc.  Announces Quarterly Dividend of $0.01
Old Second Bancorp, Inc. Announces Quarterly Dividend of $0.01
Contrasting Fuel Tech  and Clean Diesel Technologies
Contrasting Fuel Tech and Clean Diesel Technologies
Central Valley Community Bancorp  Announces Quarterly Dividend of $0.07
Central Valley Community Bancorp Announces Quarterly Dividend of $0.07
First Trust BuyWrite Income ETF  to Issue $0.08 Monthly Dividend
First Trust BuyWrite Income ETF to Issue $0.08 Monthly Dividend


© 2006-2018 Ticker Report. Google+.